Home›Research›Compare›Retatrutide vs Tirzepatide
Peptide ComparisonRetatrutide vs Tirzepatide
Both are Metabolic peptides.
Retatrutide
GLP-3
Half-life: ~6 days
96 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
541 providers listed
Tirzepatide is FDA-approved, while Retatrutide is investigational — the clearest structural difference between them.
Retatrutide
Half-life
~6 days
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Further along in FDA review | Tirzepatide |
| Less frequent dosing (longer half-life) | Tirzepatide |
| More provider options (96 vs 541) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Retatrutide
Tirzepatide
Retatrutide
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Revi…
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
+6 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Retatrutide
Class-based (investigational)
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Retatrutide
Tirzepatide
Not enough vendor pricing yet.
Where to source these peptides
Retatrutide
96 listed
Browse directory →
Providers offeringTirzepatide
541 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Retatrutide vs Tirzepatide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/retatrutide/tirzepatide